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Residues critical for establishing a trimolecular interaction with a major 
histocompatibility complex (MHC)-encoded receptor and a T cell antigen 
receptor (TcR) were determined for an antigenic nonapeptide. The N-terminal 
residue proved to be involved in binding of the peptide to both receptors and the 
C-terminal residue was essential for MHC binding. While substitution of either of 
these critical terminal residues by alanine resulted in an almost complete loss of 
peptide antigenicity, simultaneous substitution of both created a new functional 
ligand for the same MHC molecule and the sameTcR. Notably, in the biterminally 
substituted peptide, the core residues took on new roles in the trimolecular 
interaction in that a residue critical in the authentic nonapeptide for TcR binding 
became critical for MHC binding and former spacer residues became essential to 
various degrees for the interaction with either receptor or both.Thus, apparently, 
the loss of the terminal residues’ contribution was at least partially compensated 
by a redistribution of the roles among the remaining residues.These results reflect 
a cooperative contribution of all residues of an antigenic peptide to its binding to 
both receptors and thus challenge a static definition of agretope and epitope as 
MHC and TcR binding sites. 
1 Introduction 
In molecular terms, antigen recognition by T lymphocytes 
is a specific interaction between a TcR and an antigenic 
peptide bound to an MHC-encoded molecule [l-41. While 
the geometry of the presumptive peptide binding site on 
MHC molecules is known [5, 61, possible binding confor- 
mations of peptides and the final interaction of the 
peptide-MHC complex with a TcR are still largely unde- 
fined. I t  is plausible to assume that amino acid side chains in 
an antigenic peptide specify its interaction with the two 
receptors in the trimolecular MHC-peptide-TcR complex. 
As a basis for predicting the structure of the bound peptide, 
residues essential for its binding to an MHC receptor and 
residues essential for its recognition by a TcR were distin- 
guished by measuring the effects of amino acid substitu- 
tions [7-lo]. Spacer residues were defined by not being 
critically involved in the interaction with either receptor 
[7]. Here we show an example in which double substitution 
by alanine at the two critical terminal positions of an 
antigenic nonapeptide restored the interaction with the 
same receptor pair. Interestingly, this antigenicity restora- 
tion was accompanied by a redistribution of the functions 
among the core residues. 
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2 Materials and methods 
2.1 Cytolytic assay 
As effector in the antigenicity assay, a long-term line of 
CTL clone El was used that remains active and specific 
without restimulation [ l l ,  121, so that any interference 
with the assay by viral peptides from the CTL culture was 
excluded. Peptide synthesis, purification and quality con- 
trol have been described [13, 141 and details of the assay 
were given previously [ 131. 
2.2 Competition assays 
2.2.1 Autologous competition 
Ld-gene transfected L fibroblasts, that is L/Ld target cells, 
were incubated for 30min with competitor peptide at 
graded molar concentrations in culture medium before 
antigenic peptide was added. After a further 60 min, excess 
of both peptides was washed out and the cytolytic assay 
performed with CTL clone El. As antigenic peptides to be 
competed,YPHFMPTNL and APHFMPTNA were used at 
a constant, saturating concentration of lop7 M and M ,  
respectively. 
2.2.2 Heternlogous competition 
P1.HTR turn+ cells, a variant of mastocytoma P815.X2, 
served as target for recognition by CTL-P91:6 directed 
against turn- antigen P91A with 10W7 M of peptide 
P91A-.12-24 as the antigenic peptide to be competed [15]. 
The MCMV IE1 protein (pp89) nonapeptide P(168-176) 
YPHFMPTNL and its substituted analogs were tested as 
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Antigenic peptldes 
Y1PHFMPTNL9 Y'-A L9-A YLA & L%A 
i',,,, 1 , , , , ,  .i 
-10 -7 -4  -7 -4  -7 -4 -7 - 
competitors. CTL-P91:6 were propagated by weekly resti- 
mulation with mutant P91 tum- cells [15]. 
3 Results 
3.1 Mapping of residues critical for receptor interaction 
The nonapeptide YPHFMPTNL (one-letter code) is pre- 
sented by the murine MHC class I molecule Ld to theTcR of 
the CTL clone IE1 [11-131. Systematic shortening from 
both termini has identified the core sequence HFMPT as 
the minimal antigenic peptide recognized by IE1 [13]. I t  
@ I  Antigenic peptide Y HFMPTNL~ 1 1 c ' ~ i  I 
P P t h  
Y l -  C L9-A , 
-6 -4 
I 
-6 -4 
I 
Competltor peptfde [ log M 1 
Figure I. (a) Restoration of antigenicity by biterminal substitu- 
tion. Cytolytic assays measuring lytic activity of CTL clone IEl 
against Ld-gene transfected L/Ld cells incubated with the indicated 
synthetic peptides. Data represent % specific lysis standardized to 
the plateau lysis obtained with peptide YPHFMPTNL at an E/T 
plateau ratio of 10, that was 61% in the documented experiment. 
No lysis was observed without antigenic peptide or when L cells not 
expressing Ld were used as targets. (b) Competitive capacity of 
terminally substituted or truncated (a) analogs. L/Ld target cells 
were preincubated with competitor peptides before incubation 
with the antigenic nonapeptide at a close-to-plateau concentration 
(arrows). 
was concluded previously that this core must encompass all 
residues needed for specifying the contact with the El TcR 
and that the correct flanking residues enhance antigenicity 
mainly by improving the association with Ld. Despite the 
fact that even the isolated pentapeptide HFMF'T was 
recognized, deletion [13] or substitution by Ala (Fig. la)  of 
either one of the terminal residuesTyrl (Y) and Leu9 (L) of 
the nonapeptide destroyed antigenic potency almost entire- 
ly, which may mean that inappropriate flanking of the core 
forces it into a wrong conformation. Notably, simultaneous 
substitution of both critical residues largely restored anti- 
genic potency (Fig. la). Probing the capacity of substituted 
peptides to compete with the unmodified nonapeptide 
revealed an MHC-binding quality of Leu9 and an ambiva- 
lent character of Tyrl (Fig. lb). While deletion of Tyr' 
abrogated competitive ability, Ala or Gly in position 1 
mediated significant competition, but not recognition by 
clone IE1. It is concluded that the peptide backbone in 
position 1 is crucial for Ld binding of the peptide, while the 
side chain of Tyrl is needed additionally for interaction with 
the IE1 TcR. Following this strategy of testing recognition 
and functional competition, the critical quality was deter- 
mined for each position in the nonapeptide (Table 1). 
Competition against the unmodified autologous peptide, 
which is the classical version of the assay [7], allows for 
testing whether a nonantigenic analog can bind to the MHC 
molecule, but precludes an estimation of the binding 
strength relative to the unmodified antigenic peptide or to 
antigenic analogs with substitutions at spacer positions. 
This can be done, however, by competing the binding of an 
unrelated peptide to the same MHC molecule, in this case 
Ld, provided that the interaction affinities in the reference 
combination are in a similar order of magnitude or weaker. 
To date, besides the example discussed here, only two 
peptides have been identified in sequence that bind to Ld 
[15, 161. Previous work has shown that YPHFMPTNL can 
efficiently compete with Ld-binding of tum- peptide P91A 
that is recognized by an anti-P91A CTL clone [15]. This 
system was therefore employed here for heterologous 
competition (Table 1). The two types of functional compe- 
tition assays identified Pro2 and Leu9 as the most critical 
residues for MHC-binding of the peptide and Phe4 as the 
most critical residue for contacting the El TcR. In contrast 
to a previous example [7], spacer residues were not found to 
be interspersed, but formed a contiguous tetrameric stretch 
Met5 (M) to Am8 (N). 
3.2 Multiple substitutions at the termini and at spacer 
positions 
Even though the biterminally substituted peptide 
APHFMF'TNA is a more potent antigen than the N- 
terminally substituted peptide APHFMF'TNL (recall 
Fig. la) ,  it is less potent in heterologous competition 
(compare Tables 1 and 2). This finding confirms the conclu- 
sion that Tyr' has an ambivalent character in that it 
contributes to the interaction of the peptide with both its 
receptors. In accordance with the previous result that the 
pentapeptide HFh4PT is still antigenic [13], this core 
remained antigenic when flanked two-sided with two 
alanines in peptide AAHFMPTAA.Yet, MHC interaction 
of this minimal antigenic sequence was too weak for 
competing with the highly potent Ld bindersYPHFMPTNL 
and turn- ISTQNHRALPLVA (Table 2). 
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Table 1. Pattern of MHC- and TcR-binding qualities of residues in the authentic nonapeptide 
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Peptide sequence Recognition by Autologous Heterologous hlain role of 
IEla) competitionb) competitionc) residue 
Y' Pz H3 F4 M5 p6 T' N8 L9 -11 to -10 A) 1 
A o o o e o e o e  
0 A 0 0 0 0 e o e  
0 0 A 0 0 0 e 0 e  
0 0 0 A o o e o e  
0 0 0 A e e e o  
0 0 0 0 0 A e e o  
0 0 e e e o A e e  
0 0 0 0 0 0 e A e  
0 0 0 e e o e o A  
-5 to  -4 
Negativec) 
-4 to  -3 
Negative 
-12 to -11 
-11 to -10 
-11 to -10 
-11 to -10 
-410  -3 
2 
Negative') 
2 
1 - 
- 
- - 
Negative 
2 
Negative') 
2 
1 
0 to 1 
1 
1 
1 
Negative 
Y': 
P2 : 
H3: 
F1: 
M5: 
P6: 
T7: 
NS: 
L9 : 
Ambivalent 
MHC-binding 
Ambivalent 
RR-binding 
Spacer 
Spacer 
Spacer 
Spacer 
MHC-binding 
a) Minimal concentration (log M) of peptide required to measure threshold lysis with CTL clone IE1. 
b) Log excess of peptide required to reduce lysis with IE1 by > 50%. Antigenic peptide YPHFMPTNL was used at 
c) Log excess of peptide required to reduce lysis with CTL-P91:6 by > 50%. Antigenic peptide P91A-.12-24 was used at 
d) Test not possible. 
e) No recognition at M. 
f) No reduction of lysis at a 103-fold excess over the antigenic peptide. 
M. 
M. 
Table 2. Effect of biterminal and multiple spacer substitutions on antigenicity and competition capacitya) 
Pepti& sequeoa Recognition by Autologous 
IEl competition - Y' P2 I-P P Ms ps f I@ L9 -11 to -10 
A e e e e e e e A  -9 to -8 - 
A A e e e e e A A  -5 to -4 - 
e e e A A A A 0  Negative -dw 
e e 0 P P P P e  ww- 1 
Heterologous 
competition 
1 
3 
Negative 
Negative 
0-1 
a) Legend as for Table 1. 
The fact that spacer positions in YPHFh4PTNL are not 
interspersed, but consecutive, opened the opportunity to 
follow the approach of homo-oligo-amino-acid spacing 
described by Maryanski et al. [17] with the extension that 
Y P H E  . . .L analogs encompass not only all predicted MHC- 
but also all predicted TcR-binding residues. Even though, 
per definition, single Ala substitutions were tolerated in the 
spacer positions, the respective tetra-Ala analog was 
negative in both recognition and functional competition 
(Table 2), strongly indicating that the spacer residues make 
a critical cooperative contribution to peptide antigenicity. 
In striking conformity with Maryanski's example, the 
Table 3. Altered pattern of MHC- and TcR-binding qualities of core residues in the biterminally substituted analoga) 
Peptide sequence Recognition by Autologous Main role 
E l  annpetitionb) of residue 
A P 2 H 3 P M 5 P 6 T " 8 A  -9 to -8 - 
0 A e e e e . e .  Negative 
o A o e o e e 0  Negative 
0 0 e A e o o e e  Negative 
0 e e A e o e e  Negative 
e e e e A o e e  Negative 
e e e e e A e e  Negative 
o e e e o e A 4  Negative 
Nttgative Pz: MHC-binding 
3 H? Ambivalent 
Negative P: MNC-binding 
1 M5: RR-binding 
2 p6: Ambivalent 
3 p: Ambivalent 
Negative N8: MHGbinding 
a) Legend as for 'Ihble 1. 
b) Log excess of peptide required to reduce lysis with CTL clone IE1 by > 50%. As the antigenic peptide to be competed. APHFMPTNA 
was used at lop5 M. No analog of the series was able to compete with recognition of peptide P91A-12-24 by CTL-F91:6. 
1700 
tetra-Pro analog proved to be a very potent functional 
competitor.Yet, importantly, this analog was not recognized 
by clone IE1 (Table 2). 
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3.3 Redistribution of the critical contribution of core 
residues after biterminal substitution 
In view of the fact that peptide APHFMF'TNA lacks 
residues critically involved in receptor interactions, recog- 
nition by CTL clone El is a puzzling observation.We were 
considering two possibilities. Firstly, the terminal residues 
could balance each other, so that substitution of either one 
is deleterious, while substitution of both restores the 
original receptor interactions of the remaining residues. In 
that case one would expect an unchanged distribution of 
functional qualities among the core residues. Alternatively, 
the core residues might take on new roles in the substituted 
peptide to compensate the loss. Specifically, former spacer 
residues should then take a critical part. This is precisely 
what was observed (Table 3). Most prominently, Phe4 (F) 
that was the main TcR contact residue in the original 
nonapeptide turned into a critical MHC-binding residue 
and all spacer residues became essential to varying degrees 
for binding to Ld or for interacting with the IE1 TcR. 
4 Discussion 
The example shown here documents a considerable degree 
of flexibility in the roles individual residues can take when a 
peptide interacts with its receptors. It has been concluded 
before by other groups that different TcR may see different 
aspects of a particular peptide bound to a particular MHC 
molecule and, likewise, that a particular peptide may be 
presented by different or mutated MHC molecules in 
different configurations [8, 181, so that each residue of a 
given peptide has the potential to interact with either 
receptor or both, and the receptors determine which roles 
the residues actually take. Yet, our example is essentially 
different in that MHC and TcR were both kept constant. 
The observed redistribution of roles among the residues 
thus reflects an intrinsic flexibility of the peptide ligand that 
is not induced by changes in the receptors. 
The conformations that peptides can adopt as they are 
bound by MHC molecules are the subject of controversal 
views. A helical model postulating separate facades of the 
peptide for binding to the MHC molecule and theTcR [19] 
was in agreement with the distribution of MHC- and 
TcR-binding qualities in a peptide described by Allen et al. 
[7] and also with the recognition of hybrid peptides with 
shuffled facades as reported by Rothbard et al. [14]. In 
contrast, from the observation that permissible substitu- 
tions at positions critical for h4HC binding specified 
mutually exclusive recognition by either of twoTcR, Sette et 
al. proposed an extended conformation for the bound 
peptide [8] and Maryanski et al. predicted an extended 
hairpin conformation, based on a competitor analog in 
which MHC-binding residues were spaced by conforma- 
tion-constraining oligo-Pro [ 171. In  our example residues 
critical for binding to both receptors were retained by 
replacing only the spacer stretch by tetra-Pro. From the 
finding that this tetra-Pro analog was a potent competitor 
for the unmodified peptide but not a potent antigen, one 
must conclude that antigenic conformations cannot be 
predicted from conformations of competitor analogs. This 
conclusion is further substantiated by the finding that the 
same tetra-Pro analog was equally potent in competing 
with the unrelated tum-P91A peptide. 
One has to assume either that peptide APHFMPTNA 
resembles peptide YPHFMPTNL or that a conformational 
difference is tolerated by the IE1 TcR. One reasonable 
possibility is that interactions made by spacer residues were 
not critical and therefore remained cryptic in the high- 
affinity nonapeptide, but became critical and thus visible in 
the substituted low-affinity analog.That spacer residues are 
collectively involved in the formation of an antigenic 
complex is unambiguously documented by the loss of 
antigenic and competitive capacity in the tetra-Ala spacer 
analog. 
In summary, to disclose the full involvement of all residues 
in receptor interaction, substitution analysis was needed 
not only for the authentic antigenic peptide but also for a 
low-affinity analog. The ambivalent character seen then for 
many residues is not easily compatible with models postu- 
lating spatial segregation of MHC- and TcR-binding resi- 
dues. We propose that the function of a residue that is 
revealed in the assay does not describe its direct interaction 
with a receptor but rather its prevailing contribution to the 
cooperative effect of all residues. The redistribution of 
critical qualities observed in the present example is a direct 
reflection of residue cooperation. 
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